In ADCC, the Fc receptor expressed by NK cells (FcγRIII or CD16) binds to the Fc portion of the therapeutic antibody, which in turn is bound to tumor-associated antigen (TAA) on the tumor surface. Here, FCGR3A is linked to neoplasm.